DexCom, Inc. (DXCM) Yield on Cost (YOC): N/A
The yield on cost (YOC) for DexCom, Inc. (DXCM) is N/A.
DXCM Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
N/A
Interactive Yield on Cost Calculator
Project custom investment returns for DexCom, Inc. (DXCM) based on your custom cost basis.
Starting Yield
2.64%
Ending YOC
8.39%
Year 15 Dividend
$6.34
Cum. Dividends Recd.
$58.65
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $2.00 | — | 2.64% | $0.00 |
| Year 1 | $2.16 | +8.00% | 2.86% | $2.16 |
| Year 2 | $2.33 | +8.00% | 3.08% | $4.49 |
| Year 3 | $2.52 | +8.00% | 3.33% | $7.01 |
| Year 4 | $2.72 | +8.00% | 3.60% | $9.73 |
| Year 5 | $2.94 | +8.00% | 3.89% | $12.67 |
| Year 6 | $3.17 | +8.00% | 4.20% | $15.85 |
| Year 7 | $3.43 | +8.00% | 4.53% | $19.27 |
| Year 8 | $3.70 | +8.00% | 4.90% | $22.98 |
| Year 9 | $4.00 | +8.00% | 5.29% | $26.97 |
| Year 10 | $4.32 | +8.00% | 5.71% | $31.29 |
| Year 11 | $4.66 | +8.00% | 6.17% | $35.95 |
| Year 12 | $5.04 | +8.00% | 6.66% | $40.99 |
| Year 13 | $5.44 | +8.00% | 7.19% | $46.43 |
| Year 14 | $5.87 | +8.00% | 7.77% | $52.30 |
| Year 15 | $6.34 | +8.00% | 8.39% | $58.65 |
Yield on Cost (YOC) Formula
Formula: Yield on Cost = Annual Dividend / Original Purchase Price × 100
Inputs shown in the projection:
- Original purchase price.
- Annual dividend per share at the starting point.
- Assumed annual dividend growth rate.
- Projected annual dividend divided by original purchase price.
Note: Forward projections assume dividends continue to grow at the designated growth rate. Actual dividend payments are declared by corporate boards and are subject to change.
DexCom, Inc. Yield on Cost (YOC) Formula & Definition
Yield on Cost shows the dividend yield based on your original purchase price. As dividends grow, your YOC increases even if the market yield stays the same.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach